For Refractory CLL, Venetoclax's (ABT-199's) Complete Response Rate Is Tops

For Refractory CLL, Venetoclax's (ABT-199's) Complete Response Rate Is Tops

"The combination therapy of the novel anti-BCL-2 drug venetoclax (formerly ABT-199/GDC-0199, AbbVie, Genentech) and rituximab shows encouraging results in the treatment of refractory chronic lymphocytic leukemia (CLL), according to early results from an ongoing clinical trial.

The complete response rate seen with venetoclax is especially notable, said lead investigator Andrew W. Roberts, MBBS, PhD, from the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, in Australia."

medscape.com/viewarticle/84...

With thanks to Brian Koffman for bringing this to my attention.

Neil

Photo: Meadow Argus butterfly - with thanks as usual to Jay for identification

Last edited by
oldestnewest

You may also like...